Tags

Type your tag names separated by a space and hit enter

A review of compounds exhibiting anti-orthopoxvirus activity in animal models.
Antiviral Res. 2003 Jan; 57(1-2):41-52.AR

Abstract

Several animal models using mice (most frequently), rabbits, or monkeys have been used to identify compounds active against orthopoxvirus infections. The treatment of vaccinia virus infections has been well studied in models involving infection of scarified skin or eyes, or resulting from intravenous, intraperitoneal, intracerebral, or intranasal virus inoculation. Cowpox virus has been used in intranasal or aerosol infection studies to evaluate the treatment of lethal respiratory infections. Rabbitpox, monkeypox, and variola viruses have been employed to a lesser extent than the other viruses in chemotherapy experiments. A review of the literature over the past 50 years has identified a number of compounds effective in treating one or more of these infections, which include thiosemicarbazones, nucleoside and nucleotide analogs, interferon, interferon inducers, and other unrelated compounds. Substances that appear to have the greatest potential as anti-orthopoxvirus agents are the acyclic nucleotides, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (cidofovir, HPMPC) and 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine (cyclic HPMPC), and the acyclic nucleoside analog, 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine (S2242). Other classes of compounds that have not been sufficiently studied in lethal infection models and deserve further consideration are thiosemicarbazones related to methisazone, and analogs of adenosine-N(1)-oxide and 1-(benzyloxy)adenosine.

Authors+Show Affiliations

Department of Animal, Dairy and Veterinary Sciences, Institute for Antiviral Research, Utah State University, Logan, UT 84322-5600, USA. dsmee@cc.usu.eduNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.
Review

Language

eng

PubMed ID

12615302

Citation

Smee, Donald F., and Robert W. Sidwell. "A Review of Compounds Exhibiting Anti-orthopoxvirus Activity in Animal Models." Antiviral Research, vol. 57, no. 1-2, 2003, pp. 41-52.
Smee DF, Sidwell RW. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003;57(1-2):41-52.
Smee, D. F., & Sidwell, R. W. (2003). A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Research, 57(1-2), 41-52.
Smee DF, Sidwell RW. A Review of Compounds Exhibiting Anti-orthopoxvirus Activity in Animal Models. Antiviral Res. 2003;57(1-2):41-52. PubMed PMID: 12615302.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A review of compounds exhibiting anti-orthopoxvirus activity in animal models. AU - Smee,Donald F, AU - Sidwell,Robert W, PY - 2003/3/5/pubmed PY - 2003/7/31/medline PY - 2003/3/5/entrez SP - 41 EP - 52 JF - Antiviral research JO - Antiviral Res. VL - 57 IS - 1-2 N2 - Several animal models using mice (most frequently), rabbits, or monkeys have been used to identify compounds active against orthopoxvirus infections. The treatment of vaccinia virus infections has been well studied in models involving infection of scarified skin or eyes, or resulting from intravenous, intraperitoneal, intracerebral, or intranasal virus inoculation. Cowpox virus has been used in intranasal or aerosol infection studies to evaluate the treatment of lethal respiratory infections. Rabbitpox, monkeypox, and variola viruses have been employed to a lesser extent than the other viruses in chemotherapy experiments. A review of the literature over the past 50 years has identified a number of compounds effective in treating one or more of these infections, which include thiosemicarbazones, nucleoside and nucleotide analogs, interferon, interferon inducers, and other unrelated compounds. Substances that appear to have the greatest potential as anti-orthopoxvirus agents are the acyclic nucleotides, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (cidofovir, HPMPC) and 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine (cyclic HPMPC), and the acyclic nucleoside analog, 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine (S2242). Other classes of compounds that have not been sufficiently studied in lethal infection models and deserve further consideration are thiosemicarbazones related to methisazone, and analogs of adenosine-N(1)-oxide and 1-(benzyloxy)adenosine. SN - 0166-3542 UR - https://www.unboundmedicine.com/medline/citation/12615302/A_review_of_compounds_exhibiting_anti_orthopoxvirus_activity_in_animal_models_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0166354202001997 DB - PRIME DP - Unbound Medicine ER -